Literature DB >> 12390331

Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma.

Cristiano Maria Francucci1, Paola Pantanetti, Gabriella Giuseppina Garrapa, Fernando Massi, Giorgio Arnaldi, Franco Mantero.   

Abstract

OBJECTIVE: The aim of this study was to compare bone turnover and mass in women with either Cushing's syndrome (CS) or adrenal incidentaloma (AI), which is a possible model for minimal hypersecretion of cortisol. DESIGN AND PATIENTS: We studied 15 patients with CS (seven premenopausal and eight postmenopausal women); 23 patients with AI (five premenopausal and 18 postmenopausal women) and 20 matched controls (seven premenopausal and 13 postmenopausal women). Alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), osteocalcin (BGP), 24-h urinary pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) and serum and 24-h urinary calcium and phosphorus were determined in all subjects. Bone mineral density (BMD) at lumbar spine and proximal femur was measured by dual energy X-ray absorptiometry (DEXA).
RESULTS: We found a significant reduction of BGP and serum phosphorus in CS and AI (P < 0.05) vs. controls and significantly lower levels of Pyr only in CS (P < 0.05) vs. AI and controls. Spinal and femoral BMD z-values were significantly lower (P < 0.05) in patients with CS (z-score: lumbar spine -1.44 +/- 1.5 and femoral neck -1.07 +/- 1; mean +/- SD) compared to AI and controls.
CONCLUSIONS: Our data show that hypercortisolism reduces osteoblastic function and bone resorption and that osteocalcin can contribute to the precocious diagnosis of silent glucocorticoid excess. Patients with active CS were found to have lower BMD, particularly at vertebral level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390331     DOI: 10.1046/j.1365-2265.2002.01602.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Results and long-term follow-up after unilateral adrenalectomy for ACTH-independent hypercortisolism in a series of fifty patients.

Authors:  M Iacobone; F Mantero; S M Basso; F Lumachi; G Favia
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study.

Authors:  Akiko Kawamata; Masatoshi Iihara; Takahiro Okamoto; Takao Obara
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

3.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

Review 4.  Cushing's syndrome and bone.

Authors:  Tatiana Mancini; Mauro Doga; Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.

Authors:  J Majnik; N Szücs; A Patócs; M Tóth; K Balogh; I Varga; E Gláz; K Rácz
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

6.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

7.  Affective Disorders, Bone Metabolism, and Osteoporosis.

Authors:  Briana Mezuk
Journal:  Clin Rev Bone Miner Metab       Date:  2008-12

8.  The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers.

Authors:  Shobana Athimulam; Danae Delivanis; Melinda Thomas; William F Young; Sundeep Khosla; Matthew T Drake; Irina Bancos
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

Review 9.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

10.  Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX® algorithm useful?

Authors:  Laura Trementino; Letizia Ceccoli; Carolina Concettoni; Giorgia Marcelli; Grazia Michetti; Marco Boscaro; Giorgio Arnaldi
Journal:  J Endocrinol Invest       Date:  2014-07-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.